NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Revenue of NewAmsterdam Pharma Company N.V. (NAMS)
Revenue in 2023 (TTM): $12.76 M
According to NewAmsterdam Pharma Company N.V.'s latest financial reports the company's current revenue (TTM) is $12.76 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of NewAmsterdam Pharma Company N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $12.76 M | $12.76 M | $-165,687,124 | $-160,245,078 | $-160,269,534 |
| 2022 | $95.91 M | $95.91 M | $-3,313,477 | $-21,137,892 | $-21,137,892 |
| 2021 | $ | $ | $-30,726,399 | $-36,712,301 | $-36,712,301 |
| 2020 | $ | $ | $-5,428,000 | $-5,749,000 | $-5,749,000 |